to register for this live educational webinar where Dr Clarke will will discuss the advantages of assessing Alzheimer’s disease risk by measurement of the amyloid beta 42/40 ratio, describe an improved LC-MS/MS approach for amyloid beta 42/40 quantitation and apolipoprotein E phenotyping, and discuss the potential advantages of this approach relative to ELISA platforms. He will also review a new, comprehensive “risk assessment score” used to assess a patient’s risk of having Alzheimer’s disease.
Nigel J. Clarke, PhD
Vice President, Advanced Technology
Quest Diagnostics Nichols Institute
ONE contact hour toward ASCLS P.A.C.E. ® credit will be available to participating laboratory professionals who attend the webinar and complete the post evaluation.